What the National Cancer Plan for England signals for oncology innovation and access

May 27, 2026

The National Cancer Plan for England: Delivering World Class Cancer Care, published on World Cancer Day, February 4th, sets out the government’s priorities for cancer care over the next decade. The Plan places strong emphasis on improving outcomes through earlier diagnosis, faster access to treatment, and more consistent adoption of innovation across the NHS, and provides useful context for manufacturers on how access to new cancer treatments is expected to be delivered in practice.

What specific access commitments the plan sets out

The Plan sets out a number of specific commitments relevant to access to cancer treatments and the adoption of innovation. In particular, it highlights:

1. Earlier access to new cancer treatments through existing mechanisms
The Plan reaffirms the role of the Cancer Drugs Fund in enabling earlier patient access to promising cancer treatments, noting that patients in England currently receive new cancer treatments around 50% faster than the EU average. It confirms that the Fund will continue to play a role in providing earlier access to new treatments.

2. Faster regulatory and funding timelines
The Plan points to further acceleration ahead through a joint NICE-MHRA process, due by April 2026, intended to speed up licensing and appraisal timelines so that NHS funding recommendations for new medicines can be made more quickly.

3. Challenges adopting innovation at scale
The Plan acknowledges that, despite the UK’s strength in cancer research and development, evidence-based innovation has not always been adopted at scale and at pace within routine cancer care, highlighting the need for more consistent implementation of new treatments across services.

4. A clearer pathway for cancer innovation
The Plan signals the development of a clearer innovation pathway, positioning cancer as an exemplar condition for how new diagnostics and treatments are identified and adopted within the NHS.

5. Clinical trials as a core enabler of future access
Clinical trials are positioned as a critical component of the cancer innovation ecosystem. The Plan commits to establishing a Cancer Trials Accelerator Program to increase the speed, scale, and reliability of cancer trials across the UK, alongside ambitions to streamline trial delivery and increase recruitment into cancer clinical trials.

What these commitments mean for access expectations

Taken together, these commitments point to a framing of access that emphasizes speed, scalability, and delivery in practice. Approval remains a necessary milestone, but the Plan increasingly focuses on how new treatments can be adopted efficiently, consistently, and at scale once they enter the NHS.

In this context, access is less about availability in principle and more about whether innovation can be delivered reliably in routine care.

What the plan means for manufacturers planning oncology launches

For manufacturers planning future oncology launches, the National Cancer Plan reinforces that approval is no longer the sole determinant of access. As access timelines accelerate and expectations around delivery rise, there will be increasing value in understanding how therapies will be introduced into routine care, how they align with existing pathways, and where implementation friction could arise once approvals are secured. Earlier consideration of implementation, capacity, and service readiness may increasingly differentiate therapies that will move quickly into practice from those that will struggle to gain traction.

How Acumetis can support

Acumetis helps life sciences leaders reframe what’s possible by connecting evidence, access, commercial, medical, insights, and patient strategy across the asset lifecycle. In oncology, this integrated perspective is increasingly important as manufacturers navigate faster access pathways, evolving HTA expectations, and the practical realities of delivering innovation at scale within the NHS.

Our Global Value and Access experts’ understanding of access to cancer innovation is informed by direct experience. Our expert team includes consultants who have worked within NHS oncology services and understand the clinical, operational, and service-level realities that underpin access decisions.

We bring deep experience supporting oncology access strategy, including HTA and JCA activities, informed by how cancer care is delivered in practice. By combining strategic market access expertise with real-world understanding of service delivery, Acumetis helps teams build launch and access strategies that are practical, evidence-led, and aligned with the evolving expectations of cancer care in England.

Meet the Experts:

Olivia Cottom

Manager, Global Value & Access

Olivia is a healthcare consulting manager specializing in market access, with over four years of experience supporting pharmaceutical clients, particularly in oncology and hematology. She has led global and regional projects across Europe, Asia-Pacific, and Latin America focused on access strategy, reimbursement, and product differentiation. She brings expertise in HTA, value assessment, and value communication, grounded in real-world clinical experience.

FAQs on competitor analysis for gene therapy

1. What is the National Cancer Plan for England?

2. How does the National Cancer Plan affect oncology market access?

3. Why is adoption at scale becoming more important in oncology access?

4. What role do NICE and MHRA play under the new Plan?

5. What should oncology manufacturers consider in response to the Plan?